BACKGROUND: Radiofrequency (RF) energy treatment is increasingly offered before invasive surgical procedures for selected patients with gastroesophageal reflux disease (GERD). METHODS: Thirty-two patients undergoing the Stretta procedure were prospectively evaluated with upper endoscopy, manometry, 24-hour pH testing, SF-36 surveys, and GERD-specific questionnaires (GERD HRQL). RESULTS: Significant clinical improvement was observed in 91% of patients (29/32). Mean heartburn and GERD HRQL scores decreased (p = 0.001 and p = 0.003, respectively), and physical SF-36 increased (p = 0.05). At a minimum follow-up of 12 months, median esophageal acid exposure decreased (p = 0.79) and was normalized in eight patients. Median lower esophageal sphincter (LES) pressure was unchanged. Esophagitis healed in six of eight patients, but two patients with nonerosive disease developed asymptomatic grade A esophagitis during follow-up. At 12 months, 56% of patients were off proton pump inhibits. Morbidity was minimal. CONCLUSIONS: RF delivery to LES is safe and significantly improves symptoms and quality of life in selected GERD patients.
BACKGROUND: Radiofrequency (RF) energy treatment is increasingly offered before invasive surgical procedures for selected patients with gastroesophageal reflux disease (GERD). METHODS: Thirty-two patients undergoing the Stretta procedure were prospectively evaluated with upper endoscopy, manometry, 24-hour pH testing, SF-36 surveys, and GERD-specific questionnaires (GERD HRQL). RESULTS: Significant clinical improvement was observed in 91% of patients (29/32). Mean heartburn and GERD HRQL scores decreased (p = 0.001 and p = 0.003, respectively), and physical SF-36 increased (p = 0.05). At a minimum follow-up of 12 months, median esophageal acid exposure decreased (p = 0.79) and was normalized in eight patients. Median lower esophageal sphincter (LES) pressure was unchanged. Esophagitis healed in six of eight patients, but two patients with nonerosive disease developed asymptomatic grade A esophagitis during follow-up. At 12 months, 56% of patients were off proton pump inhibits. Morbidity was minimal. CONCLUSIONS:RF delivery to LES is safe and significantly improves symptoms and quality of life in selected GERD patients.
Authors: Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: George Triadafilopoulos; John K DiBaise; Timothy T Nostrant; Neil H Stollman; Paul K Anderson; M Michael Wolfe; Richard I Rothstein; John M Wo; Douglas A Corley; Marco G Patti; Louis V Antignano; John S Goff; Steven A Edmundowicz; Donald O Castell; John C Rabine; Michael S Kim; David S Utley Journal: Gastrointest Endosc Date: 2002-02 Impact factor: 9.427
Authors: B E Schenk; E J Kuipers; E C Klinkenberg-Knol; E Bloemena; G F Nelis; H P Festen; E H Jansen; I Biemond; C B Lamers; S G Meuwissen Journal: Aliment Pharmacol Ther Date: 1998-07 Impact factor: 8.171
Authors: Douglas Pleskow; Richard Rothstein; Simon Lo; Robert Hawes; Richard Kozarek; Gregory Haber; Christopher Gostout; Anthony Lembo Journal: Gastrointest Endosc Date: 2004-02 Impact factor: 9.427
Authors: D von Renteln; I Schiefke; K H Fuchs; S Raczynski; M Philipper; W Breithaupt; K Caca; H Neuhaus Journal: Surg Endosc Date: 2009-05-14 Impact factor: 4.584